Literature DB >> 26335950

CFTR, bicarbonate, and the pathophysiology of cystic fibrosis.

Drucy Borowitz1.   

Abstract

The gene that encodes for the cystic fibrosis transmembrane regulator protein (CFTR) was identified in 1989, yet major pathophysiologic questions remain unanswered. There is emerging evidence that CFTR is a bicarbonate channel, a driver of chloride-bicarbonate exchange and through its action on local pH, a regulator of other ion channels and of proteins that function optimally in a neutral environment. In both the respiratory and gastrointestinal (GI) tracts, bicarbonate drives ionic content and fluid on epithelial surfaces, allows mucins to unfold and become slippery, and contributes to innate immunity. In the GI tract bicarbonate neutralizes gastric acid to support digestion and absorption. When CFTR is dysfunctional, lack of bicarbonate secretion disrupts these normal processes and thus leads directly to the clinical symptoms and signs of CF. This article synthesizes evidence from cell, animal, and human investigations that support these concepts. Bicarbonate secretion does not seem to be the same in all tissues and varies with physiologic demand. Thus, tissue type and whether conditions are baseline or stimulated needs to be taken into account when evaluating the evidence concerning the role of bicarbonate in the pathophysiology of CF as a regulator of local pH. Basic and applied research that focuses on the role of CFTR-mediated bicarbonate secretion helps explain many of the diverse clinical manifestations that are CF.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cystic fibrosis (CF)

Mesh:

Substances:

Year:  2015        PMID: 26335950     DOI: 10.1002/ppul.23247

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  28 in total

1.  CrossTalk proposal: mucosal acidification drives early progressive lung disease in cystic fibrosis.

Authors:  Miriam F Figueira; Megan J Webster; Robert Tarran
Journal:  J Physiol       Date:  2018-07-17       Impact factor: 5.182

Review 2.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

3.  Chloride Conductance, Nasal Potential Difference and Cystic Fibrosis Pathophysiology.

Authors:  Elenara da Fonseca Andrade Procianoy; Fernando Antônio de Abreu E Silva; Paulo José Cauduro Maróstica; Paul M Quinton
Journal:  Lung       Date:  2019-11-16       Impact factor: 2.584

4.  Probability of high-risk genetic matching with oocyte and semen donors: complete gene analysis or genotyping test?

Authors:  Marta Molina Romero; Alberto Yoldi Chaure; Miguel Gañán Parra; Purificación Navas Bastida; José Luis Del Pico Sánchez; Ángel Vaquero Argüelles; Paloma de la Fuente Vaquero; Juan Pablo Ramírez López; José Antonio Castilla Alcalá
Journal:  J Assist Reprod Genet       Date:  2022-01-29       Impact factor: 3.412

Review 5.  One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.

Authors:  Marjolein M Ensinck; Marianne S Carlon
Journal:  Cells       Date:  2022-06-08       Impact factor: 7.666

6.  Tobramycin and bicarbonate synergise to kill planktonic Pseudomonas aeruginosa, but antagonise to promote biofilm survival.

Authors:  Karishma S Kaushik; Jake Stolhandske; Orrin Shindell; Hugh D Smyth; Vernita D Gordon
Journal:  NPJ Biofilms Microbiomes       Date:  2016-05-25       Impact factor: 7.290

7.  The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.

Authors:  Michael M Maiden; Mitchell P Zachos; Christopher M Waters
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.758

8.  Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms.

Authors:  Michael M Maiden; Alessandra M Agostinho Hunt; Mitchell P Zachos; Jacob A Gibson; Martin E Hurwitz; Martha H Mulks; Christopher M Waters
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.938

Review 9.  Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Authors:  Anjali Y Bhagirath; Yanqi Li; Deepti Somayajula; Maryam Dadashi; Sara Badr; Kangmin Duan
Journal:  BMC Pulm Med       Date:  2016-12-05       Impact factor: 3.317

Review 10.  Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota.

Authors:  Wolfgang Bernhard
Journal:  Eur J Nutr       Date:  2020-08-14       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.